Clinical trial
A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis
NCT01879683 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis
- Lead sponsor
- Allergan
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2013
- Completion date
- June 30, 2014
- Enrollment
- 10 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
chronic interstitial cystitis